Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

BackgroundTransmission blocking vaccines targeting the sexual-stages of the malaria parasite could play a major role to achieve elimination and eradication of malaria. The Plasmodium falciparum Pfs25 protein (Pfs25) is the most clinically advanced candidate sexual-stage antigen. IMX313, a complement...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Hans de Graaf, Ruth O. Payne, Iona Taylor, Kazutoyo Miura, Carol A. Long, Sean C. Elias, Marija Zaric, Angela M. Minassian, Sarah E. Silk, Lee Li, Ian D. Poulton, Megan Baker, Simon J. Draper, Diane Gbesemete, Nathan J. Brendish, Filipa Martins, Arianna Marini, David Mekhaiel, Nick J. Edwards, Rachel Roberts, Johan Vekemans, Sarah Moyle, Saul N. Faust, Eleanor Berrie, Alison M. Lawrie, Fergal Hill, Adrian V. S. Hill, Sumi Biswas
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2021-07-01
סדרה:	Frontiers in Immunology
נושאים:	Pfs25 malaria transmission-blocking IMX313 vaccine
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.694759/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!